Related Experiment Video
Updated: Sep 13, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Evaluation of diverse polygenic risk score models for lung cancer in a small-scale Chinese cohort
Min Gao1,2,3, Qiwen Zheng4,5, Yue Jiang6
1The First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Introduction:
Lung cancer is a leading cause of cancer-related mortality globally, with distinct epidemiological and genetic patterns in East Asian populations. However, most polygenic risk score (PRS) models have been developed using European-ancestry cohorts, raising concerns about their applicability in non-European populations.
Materials And Methods:
In this study, we systematically evaluated the predictive performance of three PRS approaches in a Chinese lung cancer cohort consisting of 97 cases and 667 controls. We assessed (i) a previously reported 19-SNP PRS developed in Chinese individuals, (ii) genome-wide PRS derived using PRS-CS with East Asian and European GWAS summary statistics, and (iii) PRS-CSx, a cross-population Bayesian framework that integrates summary statistics across ancestries.
Results:
The 19-SNP PRS demonstrated limited discriminative power in our cohort. In contrast, PRS-CS using East Asian summary statistics showed significant associations with overall lung cancer and specific histological subtypes, particularly NSCLC and LUAD. PRS-CS based on European data yielded weaker performance, underscoring the importance of ancestry matching. Notably, PRS-CSx outperformed single-ancestry models, achieving improved risk stratification for NSCLC and LUAD. However, its predictive performance for LUSC and SCLC remained limited, likely due to sample size constraints and subtype heterogeneity.
Conclusion:
Our findings emphasize the critical role of ancestry-matched data and integrative PRS approaches in enhancing risk prediction in underrepresented populations. PRS-CSx represents a promising tool for lung cancer risk assessment in East Asians, though further validation in larger cohorts are needed to improve generalizability and clinical utility.

